Publications by authors named "Paul Frewer"

Claim this Profile
O
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Ryan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, Lecia V Sequist, Ji-Youn Han, Paul Frewer

Cancer Discov· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in Oncology.
Kristine Broglio, Jayne Marshall, Binbing Yu, Paul Frewer

Ther Innov Regul Sci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam.
Song Ren, Karthick Vishwanathan, Mireille Cantarini, Paul Frewer, Indira Hara

Br J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Paul Frewer

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Paul Frewer

Lancet Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Paul K Paik, Ronglai Shen, Michael F Berger, David Ferry, Jean-Charles Soria, Paul Frewer

Clin Cancer Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Paul A Dickinson, Mireille V Cantarini, Jo Collier, Paul Frewer, Scott Martin

Drug Metab Dispos· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decision-making in early clinical drug development.
Paul Frewer, Pat Mitchell, Claire Watkins, James Matcham

Pharm Stat· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Pasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, David Planchard, Yuichiro Ohe, Paul Frewer

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Marc E Rothenberg, Amy D Klion, Florence E Roufosse, Jean Emmanuel Kahn, Peter F Weller, Paul I H Frewer

N Engl J Med· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
Wolfgang H Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Paul Frewer

Mov Disord· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients.
Andrea F Attanasio, Simon Howell, Peter C Bates, Paul Frewer, John Chipman

J Clin Endocrinol Metab· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms.
Anne Kehely, Peter C Bates, Paul Frewer, Martin Birkett, Werner F Blum

J Clin Endocrinol Metab· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood.
Andrea F Attanasio, Simon Howell, Peter C Bates, Werner F Blum, Paul Frewer

Clin Endocrinol (Oxf)· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis